In our projects, we aim to create products that are computationally, robotically, and materially novel, transitioning from traditional assembly to using robots and microbes.

The next century will be about learning how to design biology and program DNA, leading to a new generation of designers focused on biological systems.

Building a diverse team of experts in AI, chemistry, and biology is essential for questioning traditional approaches and fostering innovation in drug design.

New material combinations present great opportunities for designers, and we must always keep an open eye on technological advancements.

There's significant potential for breakthroughs by merging different subject areas, and I've always aimed to be multidisciplinary in my own work, integrating neuroscience, machine learning, and computer science.

To achieve transformative drug design, we need several more breakthroughs similar to AlphaFold, focusing on different core concepts of biology and chemistry.

Drug design is complex, with numerous bottlenecks before reaching clinical trials, and we need to innovate in this space to improve the process.

To create synthetic data sets for complex systems, we need a comprehensive catalog of components that is significantly larger than the typical system design, potentially requiring hundreds of millions of parts.

The best scientists are those who can generate creative ideas and execute them, often by making connections between disparate fields that others might overlook. To achieve this, you need to read a lot of papers across various domains, including chemical biology, molecular biology, and AI, to traverse the boundaries between disciplines.